Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.44 |
| ▸ | MPI | P34949 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10254267 | 0.84 | GLA (0.53) | GLASMN1; SMN2ALDH1A1KMT2AMAPT | |
| SCHEMBL27976380 | 0.82 | ALDH1A1 (0.54) | SMN1; SMN2ALDH1A1KMT2AMAPTLMNA | |
| SCHEMBL1473066 | 0.80 | KDM4E (0.55) | GLASMN1; SMN2ALDH1A1MAPTRAB9A | |
| SCHEMBL18389827 | 0.80 | PAOX (0.48) | ALDH1A1MAPTLMNAPAOXTSHR | |
| SCHEMBL14871082 | 0.78 | PKM (0.45) | SMN1; SMN2ALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL12251997 | 0.78 | ALDH1A1 (0.48) | SMN1; SMN2ALDH1A1KMT2AMAPTLMNA | |
| SCHEMBL1286679 | 0.78 | GLA (0.64) | GLASMN1; SMN2ALDH1A1KMT2AMAPT | |
| SCHEMBL11289764 | 0.78 | GLA (0.39) | GLASMN1; SMN2ALDH1A1MAPTLMNA | |
| SCHEMBL28005538 | 0.77 | GLA (0.69) | GLASMN1; SMN2ALDH1A1KMT2AMAPT | |
| SCHEMBL20641807 | 0.77 | ALDH1A1 (0.38) | GLAALDH1A1KMT2AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3954749-A | MORPHOLINE DERIVATIVES OF AMIDES | UNION CARBIDE CORPORATION (US) | 1976-05-04 | — | — | US | claimed |
| CN-103880575-B | Method for preparing beta-amino amide derivatives | UNIV TAIZHOU | 2015-06-03 | — | — | CN | disclosed |
| CN-103880575-A | Method for preparing beta-amino amide derivatives | UNIV TAIZHOU | 2014-06-25 | — | — | CN | disclosed |
| EP-1591443-B1 | PYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-7666869-B2 | to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I]:** Image-1wherein symbols in the formula have the following meanings;A: CH2 or S , antidiabetic agents | MITSUBISHI TANABE PHARMA CORP. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20080153821-A1 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. | 2008-06-26 | — | — | US | disclosed |
| US-20080125409-A1 | 1,5-Diheterocycle-1H-Triazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-29 | — | — | US | disclosed |
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-7332487-B2 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2008-02-19 | — | — | US | disclosed |
| EP-1785418-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-16 | — | — | EP | disclosed |
| EP-1762568-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-20060189591-A1 | Five-membered heterocyclic derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | disclosed |
| CN-1774435-A | 5-membered heterocyclic derivative | DAIICHI SEIYAKU CO (JP) | 2006-05-17 | — | — | CN | disclosed |
| EP-1621537-A1 | FIVE-MEMBERED HETEROCYCLIC DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-02-01 | — | — | EP | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
| US-4012445-A | Beta-amino carbonyl catalysts for polyurethane preparation | UNION CARBIDE CORPORATION (US) | 1977-03-15 | — | — | US | disclosed |
| US-4011223-A | POLYMERIZATION CATALYSTS, POLYURETHANES | UNION CARBIDE CORPORATION (US) | 1977-03-08 | — | — | US | disclosed |
| US-3954749-A | MORPHOLINE DERIVATIVES OF AMIDES | UNION CARBIDE CORPORATION (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125409-A1 | 1,5-Diheterocycle-1H-Triazole Derivative | PTGS1, PTGER1, TBXA2R | GLA 4244/4885SMN1; SMN2 3713/4885ALDH1A1 185/4885 |
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | GLA 2494/4885SMN1; SMN2 3778/4885ALDH1A1 139/4885 |
| US-20080064682-A1 | Pyrazole Derivatives | NAT1, AR, CBR3 | GLA 4174/4885SMN1; SMN2 3660/4885ALDH1A1 248/4885 |
| US-20060189591-A1 | Five-membered heterocyclic derivative | PTGS1, PTGIS, PTGS2 | GLA 1793/4885SMN1; SMN2 3027/4885ALDH1A1 251/4885 |
| US-20080153821-A1 | Nitrogen-containing 5-membered ring compound | ALK, SCO2, NPR1 | GLA 4245/4885SMN1; SMN2 759/4885ALDH1A1 2491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.